Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia

Disclosures: Conflicts of Interest Disclosure: The authors have no relevant conflicts of interest.

Contributions: Authorship Contributions ND and SO wrote the paper; SO, DT and HK designed and coordinated the study; DT, FR, JC, EJ, GM, GB, TK, MR, MK, HK, SO enrolled the patients and conducted the research; and RG, ND analysed the data and performed the statistics. All of the authors participated in the discussion, have reviewed and approved the current version of the manuscript.